-
From patient characteristics to treatment patterns, these MET exon 14 jumping mutation related studies on WCLC are worth a look!
Time of Update: 2022-11-15
*For medical professionals onlyThese studies from the WCLC can provide many valuable reference information for clinical diagnosis and treatment. The World Lung Cancer Conference (WCLC) is one of the m
-
Li Yaping's team at Shanghai Institute of Materia Medica, regulates nanoparticles through cholesterol metabolism to improve the effect of tumor photodynamic-immunotherapy
Time of Update: 2022-11-15
Photodynamic therapy (PDT)-mediated immune activation makes it both effective as tumor immunotherapy. However, the efficacy of PDT immunity is affected by the function and status of tumor-infiltrating
-
Antitumor peptide immune checkpoint inhibitors
Time of Update: 2022-11-15
Inhalation is not equal to nasal spray, what is the difference between the two vaccination methods?【Route of administration】Gastrointestinal administration and lung administrationAnalysis of the latest patent layout of key PI3K inhibitorsOrphan Drug Development: Shelter the World for Patients with Rare Diseases【Route of administration inventory】Ocular administrationClick "Read Original" to keep abreast of industry trendsCTLA-4 or CTLA4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152, is a protein receptor that acts as an immune checkpoint and downregulates the immune response.
-
The effect of local failure after RT in "evidence-based medicine" on the prognosis of prostate cancer patients
Time of Update: 2022-11-15
e. , dose escalation and androgen deprivation therapy) affect the development of distant metastases and other clinical outcomes, is of certain research value and significance for predicting the prognosis of patients with intermediate- and high-risk PCa. The US research team conducted this evidence-based study to assess the impact of local failure on prognosis and the dynamics of distant metastases after RT.
-
OS Super 59 months! Lung cancer brain metastasis recurred 3 degrees, and immunotherapy brought amazing results
Time of Update: 2022-11-15
After 1 cycle of treatment with temozolomide combined with pembrolizumab, the left frontal lobe and cerebellum of craniocerebral metastases continued to shrink (Fig. 2, 2b), but brain MRI showed new metastases in the right occipital lobe with a maximum diameter of 1.
-
Clinical necessity Re-radiotherapy for recurrent glioblastoma
Time of Update: 2022-11-15
Using stereotactic radiosurgery (SRS) or stereotactic radiation therapy (SRT), either hypofractionated or conventionally fractionated, several studies have shown a benefit in survival after re-irradiation in patients with relapsed GBM; However, questions remain to be answered about the effectiveness and toxicity of second course of radiation therapy.
-
The road is like a bridge, the walker has no boundaries - CSCO Autologous Transplantation Working Group 2022 Tour (Shanghai Station) was a complete success
Time of Update: 2022-11-15
On October 27, 2022, the "CSCO Autologous Transplantation Working Group 2022 Tour - Shanghai Station" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee, CSCO Le
-
Immunotherapy options for mantle cell lymphoma progressing after BTK inhibitor therapy
Time of Update: 2022-11-15
Over the past decade, Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment and management of recurrent mantle cell lymphoma (MCL). BTK inhibitors such as ibrutinib, acalabrutinib,
-
Professor Wang Jianxiang: Selinisol takes into account both efficacy and safety, bringing a new option for dual-optimal treatment for AML patients
Time of Update: 2022-11-15
Acute myeloid leukemia (AML) is a malignant clonal disease derived from hematopoietic stem cells, which tends to occur in the elderly, with a median age of onset of 66 years, and the incidence increas
-
Dual-target combination, composing music for "raw" Domestic trastuzumab combined with pertuzumab neoadjuvant therapy to win the "breast defense battle" for young breast cancer patients
Time of Update: 2022-11-15
Initial diagnosis: invasive carcinoma of the right breast, grade IIIAfter treatmentNeoadjuvant therapy: patients received a six-cycle "docetaxel + carboplatin + trastuzumab + pertuzumab" (TCbHP) regimen from 2021-10 to 2022-3.
-
Express 90% chance of maintaining refractory tumor response for more than half a year! Pfizer's bispecific antibody was designated as a breakthrough therapy
Time of Update: 2022-11-15
▎WuXi AppTec content team editorPfizer today announced that its cancer immunotherapy elranatamab has received Breakthrough Therapy Designation (BTD) from the U.
[1] Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma.
-
Interview with Professor Ma Fei|: Interpretation of the highlights of the new version of the "Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China" - standardized, innovative and leading, which is more in line with China's national conditions
Time of Update: 2022-11-15
A few days ago, the "Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer in China (2022 Edition)" (hereinafter referred to as the "Guidelines") jointly compiled by the Br
-
Prof. Jianqing Mi: JCO published the results of the Phase II CARTIFAN-1 clinical study of Sida Oquirenxel
Time of Update: 2022-11-15
MM is one of the common blood diseases in China, almost every MM patient will experience 1 to multiple recurrences, can you please talk about the current status and challenges of RRMM diagnosis and treatment based on your previous diagnosis and treatment experience?Professor Mi JianqingIn recent years, although the median survival of MM has been significantly improved with the emergence of some new drugs, including PI, IMiDs, CD38 monoclonal antibodies, and nuclear protein output inhibitors, it is still not curable.
-
This article reviews the research status and future of KRAS-targeted therapy in the field of RAS pathway and lung cancer
Time of Update: 2022-11-15
Table 1 Selected KRAS-targeted therapiesClinically used KRAS G12C inhibitorPhase I/II CodeBreaK 100 Study – Preliminary human trial data from 22 patients with advanced KRAS G12C-mutant solid tumors receiving sotorasib showed monotherapy antitumor activity.
-
Another indication was approved, and serplulimab opened the first scene of harvest in the field of lung cancer
Time of Update: 2022-11-15
Enrich treatment options in the field of non-small cell lung cancerAs a recombinant humanized anti-PD-1 monoclonal antibody injection, among the many PD-1 products that have been marketed at home and abroad, the differences of serplulimab are reflected in the molecular design, clinical trial design and indication layout.
-
Revealing new mechanisms of ovarian cancer risk and drug resistance!
Time of Update: 2022-11-15
*For medical professionals only, two studies by the same team have said this. . . . Executive summaryOn October 10, a study published in the Journal of the National Cancer Institute identified four ne
-
Trop2 ADC drug competition: who will be better
Time of Update: 2022-11-15
Meanwhile, a phase II clinical trial (NCT05351788) began evaluating the antitumor activity of SKB264 in combination with KL-A167 in advanced or metastatic non-small cell lung cancer.
Meanwhile, a phase II clinical trial (NCT05351788) began evaluating the antitumor activity of SKB264 in combination with KL-A167 in advanced or metastatic non-small cell lung cancer.
-
Professor Zhou Caicun: Serplulimab has been approved as a first-line indication for lung squamous cell carcinoma, and two high-level international studies have led PD-1 inhibitors
Time of Update: 2022-11-15
On November 1, the innovative PD-1 inhibitor sylplulimab (trade name: Hans-form ®) combined with chemotherapy (carboplatin and albumin paclitaxel) independently developed by China was approved for the
-
New progress! CTC greater than 0.07% can effectively predict the prognosis of patients with multiple myeloma
Time of Update: 2022-11-15
Figure 4In landmark analysis at 12 months post-diagnosis, a combined evaluation of baseline CTC and pre-treatment MRD status showed the best prognosis in patients with low-level CTC MRD (PFS rate 78% at 4 years post-diagnosis; OS rate was 96% at 4 years after diagnosis), while patients with high levels of CTC MRD had poor outcomes (4-year PFS rate 37%; 4-year OS rate is 66%).
-
5-year EFS rate 95.2%, 5-year OS rate 100%! Rituximab combined with LMB-containing chemotherapy regimen has outstanding efficacy in ≤ 18-year-old patient with primary mediastinal large B-cell lymphoma!
Time of Update: 2022-11-15
Poke "Read Original" to see moreThe above results show that rituximab + LMB chemotherapy has good efficacy in PMBCL patients aged ≤ 18 years, with a 5-year EFS rate of 95.
